iX Biopharma Yönetim

Yönetim kriter kontrolleri 2/4

Şu anda CEO hakkında yeterli bilgiye sahip değiliz.

Anahtar bilgiler

Eddy Lee

İcra Kurulu Başkanı

n/a

Toplam tazminat

CEO maaş yüzdesi	n/a
CEO görev süresi	16.8yrs
CEO sahipliği	22.3%
Yönetim ortalama görev süresi	3.8yrs
Yönetim Kurulu ortalama görev süresi	6.8yrs

Son yönetim güncellemeleri

Recent updates

CEO

Eddy Lee (70 yo)

16.8yrs

Görev süresi

Mr. Yip Hang Lee, also known as Eddy, serves as the Chief Executive Officer of iX Biopharma Ltd. and has been its Executive Chairman since January 17, 2008. Mr. Lee is responsible for running the affairs o...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Chin Beng Lim	Chief Pharmacist	3.8yrs	Veri yok	Veri yok
Yip Hang Lee	Executive Chairman & CEO	no data	Veri yok	22.25% SGD 4.7m
Sien Lup Chew	Chief Financial Officer	8.6yrs	Veri yok	Veri yok
Janakan Krishnarajah	COO & Chief Medical Officer	5.6yrs	Veri yok	0.69% SGD 146.2k
Iain Cook	Chief Scientist	9.2yrs	Veri yok	Veri yok
Eva Tan	Chief Commercial Officer	3.8yrs	Veri yok	Veri yok
Kuan Loong Lai	Secretary	2.8yrs	Veri yok	Veri yok
Soo Fern Lee	Secretary	2.8yrs	Veri yok	Veri yok

3.8yrs

Ortalama Görev Süresi

64yo

Ortalama Yaş

Deneyimli Yönetim: 42C 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 3.8 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Yip Hang Lee	Executive Chairman & CEO	16.8yrs	Veri yok	22.25% SGD 4.7m
Patrick Donald Davies	Non-Executive Lead Independent Director	4.9yrs	Veri yok	Veri yok
Shing Tung Ho	Non-Executive Non-Independent Director	11.7yrs	Veri yok	1.26% SGD 267.3k
Bob Rappaport	Member of Scientific Advisory Board	8.6yrs	Veri yok	Veri yok
Stephan A. Schug	Member of Scientific Advisory Board	no data	Veri yok	Veri yok
Yandi Liu	Member of Scientific Advisory Board	3.8yrs	Veri yok	Veri yok
Woon Keng Teo	Independent Non-Executive Director	2yrs	Veri yok	Veri yok

6.8yrs

Ortalama Görev Süresi

57yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: 42C 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 6.8 yıldır).

iX Biopharma Yönetim

Yönetim kriter kontrolleri 2/4

Anahtar bilgiler

Son yönetim güncellemeleri

iX Biopharma Ltd. Announces Reconstitution of the Board Committees

iX Biopharma Ltd., Annual General Meeting, Oct 17, 2024

iX Biopharma Ltd., Annual General Meeting, Oct 13, 2023

iX Biopharma Ltd. Announces Board and Committee Appointment

iX Biopharma Ltd., Annual General Meeting, Oct 14, 2022

iX Biopharma Ltd. Announces Cessation of Yee Chia Hsing as Director of Corporate Affairs & General Manager of Entity Health Ltd

Recent updates

iX Biopharma Ltd. Announces Reconstitution of the Board Committees

Full year 2024 earnings released: S$0.014 loss per share (vs S$0.013 loss in FY 2023)

iX Biopharma Ltd., Annual General Meeting, Oct 17, 2024

Full year 2024 earnings released: S$0.014 loss per share (vs S$0.013 loss in FY 2023)

New minor risk - Financial data availability

New minor risk - Shareholder dilution

New major risk - Financial position

iX Biopharma Ltd., Annual General Meeting, Oct 13, 2023

Full year 2023 earnings released: S$0.013 loss per share (vs S$0.006 loss in FY 2022)

New major risk - Share price stability

New minor risk - Financial data availability

iX Biopharma Ltd. announced that it has received SGD 2 million in funding

iX Biopharma Ltd. announced that it expects to receive SGD 2 million in funding

First half 2023 earnings released: S$0.01 loss per share (vs S$0.005 profit in 1H 2022)

iX Biopharma Ltd Successfully Completes Phase 1 Sublingual Dexmedetomidine Clinical Study

Forecast to breakeven in 2024

iX Biopharma Ltd. Announces Board and Committee Appointment

iX Biopharma Ltd., Annual General Meeting, Oct 14, 2022

Full year 2022 earnings released: S$0.006 loss per share (vs S$0.012 loss in FY 2021)

iX Biopharma Ltd. has completed a Follow-on Equity Offering in the amount of SGD 2.742 million.

iX Biopharma Ltd. Announces Drug Development Updates for Wafermine and Wafesil

iX Biopharma Ltd. Announces Cessation of Yee Chia Hsing as Director of Corporate Affairs & General Manager of Entity Health Ltd

Price target decreased to S$0.34

First half 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

iX Biopharma Ltd. Announces Executive Changes

iX Biopharma Ltd Appoints Angeline Tham as Non-Executive Independent Director, Member of Audit Committee and Remuneration Committee and Chairperson of Nominating Committee, Effective 1 February 2022

No longer forecast to breakeven

Price target decreased to S$0.34

Full year 2021 earnings released: S$0.012 loss per share (vs S$0.016 loss in FY 2020)

Full year 2021 earnings released: S$0.008 loss per share (vs S$0.016 loss in FY 2020)

Executive Chairman & CEO exercised options to buy S$2.7m worth of stock.

iX Biopharma Ltd to Participate in Study with Wafermine for Treatment of Breakthrough Pain in Advanced Cancer Patients

iX Biopharma Ltd. Appoints Yee Chia Hsing as Director of Corporate Affairs

First half 2021 earnings released: S$0.004 loss per share (vs S$0.009 loss in 1H 2020)

iX Biopharma Ltd. Appoints Ms. Eva Tan as Its New Chief Commercial Officer

Full year earnings released - S$0.016 loss per share

New 90-day low - S$0.23

iX Biopharma Ltd. has completed a Follow-on Equity Offering in the amount of SGD 10.232999 million.

Full year earnings released

New 90-day high - S$0.34

CEO

Görev süresi

Liderlik Ekibi

Ortalama Görev Süresi

Ortalama Yaş

Yönetim Kurulu Üyeleri

Ortalama Görev Süresi

Ortalama Yaş